Yingqi Xu
4PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Apr 25, 2025
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC.Yingqi Xu, Yidan Zhang, Hongping Jin
|Mar 19, 2025
Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.Yidan Zhang, Yingqi Xu, Hongping Jin
|Dec 31, 2024
Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.Yidan Zhang, Yingqi Xu, Jianlin Xu
|Mar 26, 2024
Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.Yingqi Xu, Hao Ji, Yidan Zhang
Pageof 1
